vitamin k-4

K-Ras G12C-IN-4, is a potent Covalent Inhibitor of KRASG12C..

K-Ras ligand-Linker Conjugate 4 is a chemical compound that combines a ligand for K-Ras recruiting moiety with a PROTAC linker. This linker is responsible for recruiting E3 ligases such as VHL, CRBN, MDM2, and IAP. The compound has the potential to be used in the synthesis of PROTAC K-Ras Degrader-1, a powerful degrader of K-Ras that has been shown to exhibit a degradation efficacy of ≥70% in SW1573 cells[1].

Antibiotic K 4 is an inhibitor of angiotensin I converting enzyme produced by Actinomadura spiculosospora.

Vitamin K (Kephton) has blood coagulation action and is important for coagulation factors, matrix-Gla protein, and osteocalcin.

c(phg-isoDGR-(NMe)k) TFA is a potent and selective α5β1-integrin ligand (IC50: 2.9 nM).

Vitamin K4 (Menadiol Diacetate) is a vitamin medicine for the treatment of blood coagulation disorders that caused by the lack of VK4.

Menaquinone-4 (Vitamin K2) is a vitamin K compound used as a hemostatic agent, and also as adjunctive therapy for the pain of osteoporosis.

Betrixaban (PRT054021) is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4].

Betrixaban maleate is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa.